Combined administration of platelet rich plasma and autologous bone marrow aspirate concentrate for spinal cord injury: a descriptive case series.

Oswestry Disability Index bone marrow aspirate concentrate cell-based therapy neural regeneration platelet rich plasma spinal cord injury stem cells

Journal

Neural regeneration research
ISSN: 1673-5374
Titre abrégé: Neural Regen Res
Pays: India
ID NLM: 101316351

Informations de publication

Date de publication:
Feb 2021
Historique:
entrez: 30 8 2020
pubmed: 30 8 2020
medline: 30 8 2020
Statut: ppublish

Résumé

Administration of platelet rich plasma (PRP) and bone marrow aspirate concentrate (BMAC) has shown some promise in the treatment of neurological conditions; however, there is limited information on combined administration. As such, the purpose of this study was to assess safety and functional outcomes for patients administered combined autologous PRP and BMAC for spinal cord injury (SCI). This retrospective case series included seven patients who received combined treatment of autologous PRP and BMAC via intravenous and intrathecal administration as salvage therapy for SCI. Patients were reviewed for adverse reactions and clinical outcomes using the Oswestry Disability Index (ODI) for up to 1 year, as permitted by availability of follow-up data. Injury levels ranged from C3 through T11, and elapsed time between injury and salvage therapy ranged from 2.4 months to 6.2 years. Post-procedure complications were mild and rare, consisting only of self-limited headache and subjective memory impairment in one patient. Four patients experienced severe disability prior to PRP combined with BMAC injection, as evidenced by high (> 48/100) Oswestry Disability Index scores. Longitudinal Oswestry Disability Index scores for two patients with incomplete SCI at C6 and C7, both of whom had cervical spine injuries, demonstrated a decrease of 28-40% following salvage therapy, representing an improvement from severe to minimal disability. In conclusion, intrathecal/intravenous co-administration of PRP and BMAC resulted in no significant complications and may have had some clinical benefits. Larger clinical studies are needed to further test this method of treatment for patients with SCI who otherwise have limited meaningful treatment options. This study was reviewed and approved by the OhioHealth Institutional Review Board (IRB No. 1204946) on May 16, 2018.

Identifiants

pubmed: 32859799
pii: NeuralRegenRes_2021_16_2_362_290903
doi: 10.4103/1673-5374.290903
pmc: PMC7896202
doi:

Types de publication

Journal Article

Langues

eng

Pagination

362-366

Déclaration de conflit d'intérêts

None

Références

J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Neural Regen Res. 2015 May;10(5):726-42
pubmed: 26109946
World Neurosurg. 2017 Feb;98:438-443
pubmed: 27876663
Stem Cells Transl Med. 2012 Mar;1(3):237-47
pubmed: 23197783
J Orthop Surg Res. 2018 Jan 03;13(1):1
pubmed: 29298726
J Neurosci Res. 2002 Dec 15;70(6):721-33
pubmed: 12444594
Turk Neurosurg. 2012;22(2):207-17
pubmed: 22437296
Nature. 1982 Mar 11;296(5853):150-2
pubmed: 7063015
Biosci Rep. 2015 Apr 28;35(2):
pubmed: 25797907
Regen Med. 2010 Nov;5(6):933-46
pubmed: 21082892
Stem Cells. 2007 Aug;25(8):2066-73
pubmed: 17464087
Cell Transplant. 2008;17(12):1277-93
pubmed: 19364066
Spinal Cord. 2016 Jan;54(1):57-64
pubmed: 26282492
Cytotherapy. 2013 Jul;15(7):792-804
pubmed: 23731762
Results Probl Cell Differ. 2009;48:339-51
pubmed: 19582408
Bone Marrow Res. 2018 Feb 25;2018:1549826
pubmed: 29682351
Stem Cells Dev. 2007 Jun;16(3):461-6
pubmed: 17610376
Curr Stem Cell Res Ther. 2019;14(8):683-697
pubmed: 31244430
Acta Orthop Traumatol Turc. 2017 May;51(3):254-257
pubmed: 28462801
Bone Res. 2016 Dec 13;4:16036
pubmed: 28018706
Front Neurosci. 2018 Apr 23;12:252
pubmed: 29740270
Expert Rev Ophthalmol. 2012 Oct 1;7(5):459-470
pubmed: 23585772
Clin Orthop Relat Res. 2014 Dec;472(12):3789-97
pubmed: 24599650
Clin Transplant. 2015 Sep;29(9):786-95
pubmed: 26115044
Ann Dermatol. 2014 Feb;26(1):1-10
pubmed: 24648680
Cell Mol Neurobiol. 2006 Oct-Nov;26(7-8):1113-29
pubmed: 16633897
Phys Ther. 2002 Jan;82(1):8-24
pubmed: 11784274
Stem Cell Res Ther. 2015 Dec 01;6:234
pubmed: 26620426
Biomed Pharmacother. 2017 Jul;91:693-706
pubmed: 28499241
Spine (Phila Pa 1976). 2000 Nov 15;25(22):2940-52; discussion 2952
pubmed: 11074683
Anat Cell Biol. 2018 Sep;51(3):180-188
pubmed: 30310710
J Neurotrauma. 2012 May 20;29(8):1614-25
pubmed: 22233298
Exp Hematol. 2006 Feb;34(2):130-1
pubmed: 16459180
Brain Res. 2013 Oct 2;1533:73-9
pubmed: 23948102
Tissue Eng. 2005 May-Jun;11(5-6):913-22
pubmed: 15998231
World J Stem Cells. 2014 Apr 26;6(2):120-33
pubmed: 24772239
Laryngoscope. 2010 May;120(5):907-13
pubmed: 20422684
Orthop J Sports Med. 2016 Jan 13;4(1):2325967115625481
pubmed: 26798765
BMC Neurosci. 2010 Sep 16;11:119
pubmed: 20846445
J Biol Regul Homeost Agents. 2012 Apr-Jun;26(2 Suppl 1):3S-22S
pubmed: 23648195
Neuroreport. 2012 Aug 22;23(12):712-6
pubmed: 22750774
Biochem Cell Biol. 2017 Oct;95(5):537-548
pubmed: 28314112
Med Hypotheses. 2009 Dec;73(6):1038-40
pubmed: 19767153
Asian J Neurosurg. 2017 Oct-Dec;12(4):681-690
pubmed: 29114283
J Stem Cells. 2016;11(1):51-61
pubmed: 28296864
Oxid Med Cell Longev. 2015;2015:632902
pubmed: 25722795

Auteurs

Joseph A Shehadi (JA)

Section of Neurosurgery at OhioHealth Grant Medical Center, Cedar Stem Cell Institute, Columbus, OH, USA.

Steven M Elzein (SM)

The Ohio State University College of Medicine, Columbus, OH, USA.

Paul Beery (P)

Division of Trauma and Acute Care Surgery, OhioHealth Grant Medical Center, Columbus, OH, USA.

M Chance Spalding (MC)

Division of Trauma and Acute Care Surgery, OhioHealth Grant Medical Center, Columbus, OH, USA.

Michelle Pershing (M)

OhioHealth Research Institute, Columbus, OH, USA.

Classifications MeSH